# US 2025/0145720 A1 · Human igg1 fc region variants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145720 A1
- Document ID: US20250145720A1
- Status: Published application
- Kind: A1
- Application number: 18/744,540
- Filed: 2024-06-14
- Published: 2025-05-08
- Earliest claimed: 2015-07-09
- Assignees: Genmab B.V.
- Applicants: Genmab B.V.
- Inventors: Paul PARREN; Frank BEURSKENS; Rob N. DE JONG; Sandra VERPLOEGEN; Aran Frank LABRIJN; Janine SCHUURMAN
- Web page: https://patentgrep.com/patent/US20250145720A1

## CPC

- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/36: against blood coagulation factors
- C07K 16/40: against enzymes
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/77: Internalization into the cell
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the poly-peptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).

## Claims

### Claim 1

A method of increasing complement-dependent cytotoxicity (CDC) and/or antibody dependent cell-mediated cytotoxicity (ADCC) of a parent polypeptide comprising an Fc domain of an immunoglobulin and a binding region, the method comprising introducing a mutation to the parent polypeptide in one or more amino acid residue(s) selected from the group corresponding to E430X, E345X, and S440W in the Fc region of a human IgG1 heavy chain, wherein X is any amino acid.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mutation in one or more amino acid residue(s) is selected from the group corresponding to E430G, E430S, E430F, E430T, E345K, E345Q, E345R, E345Y, and S440W in the Fc region of a human IgG1 heavy chain.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein the parent polypeptide is a parent antibody comprising an Fc domain of an immunoglobulin and an antigen-binding region.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the parent antibody is a monospecific, bispecific or multispecific antibody.

### Claim 8

A method of increasing complement-dependent cytotoxicity (CDC) of a parent antibody, wherein the parent antibody is a bispecific antibody comprising a first polypeptide comprising a first CH2-CH3 region of an immunoglobulin and a first antigen-binding region, and a second polypeptide comprising a second CH2-CH3 region of an immunoglobulin and a second antigen-binding region, wherein the first and second antigen-binding regions bind different epitopes on the same antigen or on different antigens, and wherein the method comprises introducing a mutation to the first and/or second CH2-CH3 region in one or more amino acid residue(s) selected from the group corresponding to E430X, E345X, S440Y and S440W in the Fc region of a human IgG1 heavy chain, wherein X is any amino acid; and
wherein the first CH2-CH3 region comprises a further amino acid mutation at a position selected from those corresponding to K409, T366, L368, K370, D399, F405, and Y407 in the Fc region of a human IgG1 heavy chain; and wherein the second CH2-CH3 region comprises a further amino acid mutation at a position selected from those corresponding to F405, T366, L368, K370, D399, Y407, and K409 in the Fc region of a human IgG1 heavy chain, and wherein the further amino acid mutation in the first CH2-CH3 region is different from the further amino acid mutation in the second CH2-CH3 region.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the mutation in one or more amino acid residue(s) is selected from the group corresponding to E430G, E430S, E430F, E430T, E345K, E345Q, E345R, E345Y, S440Y, and S440W in the Fc region of a human IgG1 heavy chain.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the method comprises introducing a mutation in both the first and second polypeptide of the bispecific antibody.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the further amino acid mutation of the first CH2-CH3 region is at the position corresponding to K409, such as K409R, in the Fc region of a human IgG1 heavy chain; and wherein the further amino acid mutation of the second CH2-CH3 region is at the position corresponding to F405, such as F405L, in the Fc region of a human IgG1 heavy chain.

### Claim 12 (depends on 1)

The method according to claim 1, the method comprising introducing the mutation in one of more positions other than S440Y and S440W, and further introducing a mutation
(i) in each of the amino acid residues corresponding to K439 and S440 in the Fc region of a human IgG1 heavy chain, with the proviso that the mutation in S440 is not S440Y or S440W,
(ii) in each of the amino acid residues corresponding to K447 and 448 in the Fc region of a human IgG1 heavy chain, such as K447K/R/H and 448E/D in the Fc region of a human IgG1 heavy chain, preferably K447K and 448E in the Fc region of a human IgG1 heavy chain, or
(iii) in each of the amino acid residues corresponding to K447, 448 and 449 in the Fc region of a human IgG1 heavy chain, such as K447D/E, 448K/R/H and 449P in the Fc region of a human IgG1 heavy chain, preferably K447E, 448K and 449P in the Fc region of a human IgG1 heavy chain.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the method comprises introducing the mutation in one of more positions other than S440Y and S440W, and further introducing a mutation in each of the amino acid residues corresponding to K439 and/or S440 in the Fc region of a human IgG1 heavy chain, with the proviso that the mutation in in S440 is not S440Y or S440W.

### Claim at position 12

14-24. (canceled)

### Claim 25 (depends on 1)

The method according to claim 1, wherein the method does not:
(a) alter antibody dependent cell-mediated cytotoxicity (ADCC) of the parent polypeptide or parent antibody,
(b) alter binding of the parent polypeptide or parent antibody to neonatal Fc receptor (FcRn) as determined by the method disclosed in Example 34;
(c) increase or decrease binding of the parent polypeptide or parent antibody to neonatal Fc receptor (FcRn) by more than 30%, such as of more than 20%, 10% or 5% as measured by a change in the absorbance at OD405 nm as determined by the method disclosed in Example 34;
(d) does not increase the apparent affinity of the parent polypeptide or parent antibody to mouse neonatal Fc receptor (FcRn) by more than a factor 0.5 or does not decrease the apparent affinity of the parent polypeptide or parent antibody to mouse FcRn by more than a factor 2 as determined by the method disclosed in Example 34;
(e) does not alter the plasma clearance rate of the parent polypeptide or parent antibody as determined by the method disclosed in Example 37;
(f) does not increase or decrease the plasma clearance rate of the parent polypeptide or parent antibody by more than a factor 3.0, such as by by more than a factor 2.5, factor 2.0, factor 1.5 or factor 1.2 as determined by the method disclosed in Example 37;
(g) does not alter target independent fluid phase complement activation of the variant as determined by the method as determined by the method disclosed in Example 36; and/or
(h) does not alter the plasma half-life of the parent polypeptide or parent antibody.

### Claim at position 14

26-32. (canceled)

### Claim 33

A variant of:
(A) a parent polypeptide comprising an Fc domain of an immunoglobulin and a binding region, wherein the variant comprises one or more mutation(s) selected from the group corresponding to E430G, E430S, E430F, E430T, E345K, E345Q, E345R, E345Y, and S440W in the Fc region of a human IgG1 heavy chain and provided that the variant does not contain any further mutations in the Fc domain which alter the binding of the variant to neonatal Fc receptor (FcRn),
(B) a parent polypeptide comprising an Fc domain of an immunoglobulin and a binding region, wherein the variant comprises a first mutation selected from the group corresponding to E430G, E430S, E430F, E430T, E345K, E345Q, E345R, E345Y, S440Y, and S440W in the Fc region of a human IgG1 heavy chain; and a second mutation selected from the group corresponding to
(i) an amino acid residue corresponding to K439 and S440 in the Fc region of a human IgG1 heavy chain, with the proviso that the mutation in S440 is not S440Y or S440W, and if the first mutation is S440Y or S440W the second mutation is in the amino acid residue corresponding to K439 in the Fc region of a human IgG1 heavy chain,
(ii) an amino acid residue corresponding to K447D/E or corresponding to K447K/R/H and 448P in the Fc region of a human IgG1 heavy chain: or
(iii) an amino acid residue corresponding to K447D/E or corresponding to K447K/R/H and 448K/R/H and 449P in the Fc region of a human IgG1 heavy chain;
(C) a parent antibody which is a bispecific antibody comprising a first polypeptide comprising a first CH2-CH3 region of an immunoglobulin and a first antigen-binding region, and a second polypeptide comprising a second CH2-CH3 region of an immunoglobulin and a second antigen-binding region, wherein the first and second antigen-binding regions bind different epitopes on the same or on different antigens, and wherein the first and/or second CH2-CH3 regions comprise one or more mutation(s) selected from the group corresponding to E430G, E430S, E430F, E430T, E345K, E345Q, E345R, E345Y, S440Y, and S440W in the Fc region of a human IgG1 heavy chain, and wherein
the first polypeptide comprises a further mutation in an amino acid residue selected from those corresponding to K409, T366, L368, K370, D399, F405, and Y407 in the Fc region of a human IgG1 heavy chain; and
the second polypeptide comprises a further mutation in an amino acid residue selected from those corresponding to F405, T366, L368, K370, D399, Y407 and K409 in the Fc region of a human IgG1 heavy chain, and wherein the further mutation in the first polypeptide is different from the further mutation in the second polypeptide.

### Claim at position 16

34-50. (canceled)

### Claim 51 (depends on 33)

The variant according to claim 33, wherein the variant is conjugated to a drug, toxin or radiolabel, such as wherein the variant is conjugated to a toxin via a linker.

### Claim 52 (depends on 33)

The variant according to claim 33, wherein the variant is part of a fusion protein.

### Claim 53 (depends on 33)

The variant according to claim 33, wherein the variant is a human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgM, or IgE antibody, optionally a human full-length antibody, such as a human full-length IgG1 antibody.

### Claim 54 (depends on 33)

A composition comprising the variant of claim 33 and a carrier.

### Claim at position 21

55-70. (canceled)

### Claim 71 (depends on 33)

A kit-of-parts comprising a first variant and a second variant, both as defined in claim 33, and instructions for use.

### Claim 72

(canceled)

### Claim 73 (depends on 33)

A method for the treatment of a disease in a human comprising administering an effective amount of the variant of claim 33.

### Claim 74 (depends on 33)

A method for the treatment of cancer in a human comprising administering an effective amount of the variant of claim 33.

### Claim 75

(canceled)

### Claim 76 (depends on 33)

A method for imaging of at least a part of the body of a human or other mammal, comprising administering to the human or other mammal the variant of claim 33.
